AI-native pharma company Formation Bio and IMIDomics, a precision medicine company focused on immune-mediated inflammatory diseases, announced on Tuesday that Formation Bio has licensed worldwide rights to IMIDomics' first-in-class anti-CD226 monoclonal antibody (mAb).

The clinical programme, which has received IND clearance, will be advanced by Formation Bio in autoimmune indications, initially ulcerative colitis.

The antibody targets CD226 (DNAM-1), a key immune checkpoint involved in regulating several key immune cells thereby affecting both innate and acquired immune responses. By blocking the interaction between CD226 and its ligands CD112 and CD155, the antibody aims to suppress immune overactivation, offering a novel approach for treating patients with autoimmune conditions.

Under the terms of the agreement, IMIDomics will receive an upfront payment and is eligible for future development and commercial milestones, as well as royalties on potential sales. In addition, IMIDomics will receive equity in Riverview Bio, a subsidiary of Formation Bio that has been formed to develop this therapy, which joins Libertas Bio and Highline Bio as part of Formation's growing portfolio of clinical stage asset-centric NewCos.